Gerald Schmid-Bindert
Overview
Explore the profile of Gerald Schmid-Bindert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
803
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmid-Bindert G, Vogel-Claussen J, Gutz S, Fink J, Hoffmann H, Eichhorn M, et al.
Respiration
. 2022 Oct;
101(11):1024-1034.
PMID: 36228594
Lung cancer (LC) is the leading cause of cancer-related mortality worldwide, and early LC diagnosis can significantly improve outcomes and survival rates in affected patients. Implementation of LC screening programs...
2.
Vogel-Claussen J, Lasch F, Bollmann B, May K, Kuhlmann A, Schmid-Bindert G, et al.
Rofo
. 2022 Aug;
194(12):1333-1345.
PMID: 35917826
Despite the high prevalence and mortality of lung cancer and proven effectiveness of low-dose computed tomography (LDCT) to reduce mortality, Germany still lacks a national screening program. The German Institute...
3.
Metzenmacher M, Kopp H, Griesinger F, Reinmuth N, Sebastian M, Serke M, et al.
Ther Adv Med Oncol
. 2021 Jun;
13:1758835921996506.
PMID: 34104223
Background: Pemetrexed and cisplatin is a first-line standard in non-squamous non-small-cell lung cancer without targetable mutations. It became the backbone of checkpoint-inhibitor-chemotherapy combinations. Single high doses of cisplatin pose toxicity...
4.
Herth F, Slebos D, Shah P, Hetzel M, Schmid-Bindert G, LaPrad A, et al.
Respiration
. 2019 Nov;
98(6):512-520.
PMID: 31743933
Background: The PneumRx endobronchial coil system for patients with severe emphysema has been shown to improve quality of life, exercise capacity, and pulmonary function in patients with emphysema. A post...
5.
Slebos D, Cicenia J, Sciurba F, Criner G, Hartman J, Garner J, et al.
Chest
. 2019 Feb;
155(5):928-937.
PMID: 30797746
Background: The Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) trial reported improvements in quality of life, pulmonary function, and exercise performance following endobronchial coil treatment. Objectives: The...
6.
Ferrer I, Zugazagoitia J, Herbertz S, John W, Paz-Ares L, Schmid-Bindert G
Lung Cancer
. 2018 Oct;
124:53-64.
PMID: 30268480
In patients with non-small cell lung cancer (NSCLC), the most frequent oncogene driver mutation in Western countries is Kirsten rat sarcoma viral oncogene homolog (KRAS), and KRAS-mutant NSCLC is associated...
7.
Li B, Ren S, Wang Y, Zhou C, Schmid-Bindert G
Thorac Cancer
. 2017 Sep;
4(2):117-122.
PMID: 28920197
Background: Recently, differences in tumor biology have been observed between Asian and Caucasian lung cancer patients, resulting in different sensitivities to targeted therapy. To date, all registered third-generation chemotherapeutic agents...
8.
Schmid-Bindert G, Engel-Riedel W, Reck M, Schuette W, Stohlmacher J, Fischer J, et al.
Lung Cancer
. 2016 Jan;
90(3):397-404.
PMID: 26791798
Objectives: We investigated the feasibility of cisplatin or carboplatin combined with pemetrexed as adjuvant treatment in patients with completely resected Stage IB/II Non-Small-Cell Lung Cancer (NSCLC). Materials And Methods: Patients...
9.
Schmid-Bindert G, Jiang T
Transl Lung Cancer Res
. 2015 Jul;
4(3):215-6.
PMID: 26207206
No abstract available.
10.
Gautschi O, Milia J, Cabarrou B, Bluthgen M, Besse B, Smit E, et al.
J Thorac Oncol
. 2015 Jul;
10(10):1451-7.
PMID: 26200454
Introduction: Approximately 2% of lung adenocarcinomas have BRAF (v-Raf murine sarcoma viral oncogene homolog B) mutations, including V600E and other types. Vemurafenib, dabrafenib, and sorafenib as BRAF inhibitors are currently...